FDA May Require More Warnings on Tamoxifen Label | DC Metro Area Medical Malpractice Law Blog

Posted by: Salvatore J. Zambri, Esquire

We recently posted a blog informing our readers that a Bloomberg report announced that researchers have determined that certain antidepressants may increase the recurrence of breast cancer among women who have already survived the disease.  The study reports that drugs including Prozac, Paxil and Zoloft “significantly decrease the effectiveness of a drug [tamoxifen] used to reduce the chances of breast cancer recurrence”.

A new Bloomberg report of yesterday confirms that “US regulators may warn patients taking tamoxifen, a breast cancer medicine…not to use certain types of antidepressants because they block the tumor-fighting drug’s effectiveness.” Karen Riley, a spokeswoman for the Food and Drug Administration, commented that the agency is considering “adding new information to the tamoxifen label to advise women taking the cancer drug against using some antidepressants.”

Ms. Riley’s comments are welcomed, but action is what is needed.  The public must be warned of the harmful effects of mixing these drugs.  It could be a matter of life and death.

Our firm has experience pursing cases for patients that involve tragic medication errors,  pharmacy mix ups, and unsafe medications. For information about your legal rights, please click here or contact us at Regan Zambri & Long, PLLC at (202) 463-3030.